Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
International Journal of Cancer|June 28, 2021
Toxicity of pemetrexed during renal impairment explained-Implications for safe treatmentRené J Boosman, Thomas P C Dorlo, Nikki de Rouw, et al.
Cancer Chemotherapy and Pharmacology|November 22, 2022
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trialNikki de Rouw, René J Boosman, Jacobus A Burgers, et al.
Targeted Oncology|June 18, 2024
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab GovitecanDirk J A R Moes, Jeroen J M A Hendrikx, Henk-Jan Guchelaar, et al.
British Journal of Clinical Pharmacology|August 10, 2021
Hyperhydration with cisplatin does not influence pemetrexed exposureNikki de Rouw, Hieronymus J Derijks, Luuk B Hilbrands, et al.
Clinical Pharmacology and Therapeutics|May 27, 2025
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal ImpairmentNikki de Rouw, Leila-Sophie Otten, Mart P Kicken, et al.
Clinical Lung Cancer|April 22, 2025
The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort StudyMart P Kicken, Rob Ter Heine, Intissar Azarfane, et al.
Targeted Oncology|April 20, 2023
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung CancerRob Ter Heine, Michel M van den Heuvel, Berber Piet, et al.
Pageof 2